Royalty Pharma plc (NASDAQ:RPRX) Shares Bought by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 6.3% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,972,201 shares of the biopharmaceutical company's stock after purchasing an additional 174,874 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.50% of Royalty Pharma worth $84,084,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in RPRX. Swedbank AB raised its position in shares of Royalty Pharma by 30.6% during the second quarter. Swedbank AB now owns 10,813,470 shares of the biopharmaceutical company's stock worth $285,151,000 after acquiring an additional 2,533,570 shares during the last quarter. Charles Schwab Investment Management Inc. raised its holdings in shares of Royalty Pharma by 58.1% in the third quarter. Charles Schwab Investment Management Inc. now owns 3,001,603 shares of the biopharmaceutical company's stock valued at $84,915,000 after purchasing an additional 1,103,341 shares during the last quarter. New South Capital Management Inc. raised its holdings in Royalty Pharma by 60.7% during the second quarter. New South Capital Management Inc. now owns 2,348,977 shares of the biopharmaceutical company's stock worth $61,943,000 after acquiring an additional 887,522 shares in the last quarter. Dark Forest Capital Management LP increased its holdings in Royalty Pharma by 2,974.4% during the second quarter. Dark Forest Capital Management LP now owns 338,675 shares of the biopharmaceutical company's stock worth $8,931,000 after buying an additional 327,659 shares during the last quarter. Finally, AQR Capital Management LLC increased its position in Royalty Pharma by 69.0% during the second quarter. AQR Capital Management LLC now owns 785,567 shares of the biopharmaceutical company's stock worth $20,715,000 after buying an additional 320,606 shares during the last quarter. 54.35% of the stock is currently owned by institutional investors and hedge funds.

Royalty Pharma Stock Performance

Shares of NASDAQ RPRX traded down $0.09 during trading on Tuesday, reaching $26.34. 3,191,189 shares of the company traded hands, compared to its average volume of 2,640,419. The firm has a 50 day simple moving average of $27.09 and a 200-day simple moving average of $27.30. Royalty Pharma plc has a 52-week low of $25.10 and a 52-week high of $31.66. The company has a quick ratio of 1.54, a current ratio of 1.54 and a debt-to-equity ratio of 0.64. The stock has a market capitalization of $15.52 billion, a PE ratio of 13.65, a P/E/G ratio of 4.64 and a beta of 0.46.

Royalty Pharma Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Friday, November 15th will be paid a dividend of $0.21 per share. This represents a $0.84 dividend on an annualized basis and a yield of 3.19%. The ex-dividend date of this dividend is Friday, November 15th. Royalty Pharma's payout ratio is presently 43.52%.

Analyst Upgrades and Downgrades

RPRX has been the subject of several analyst reports. StockNews.com upgraded shares of Royalty Pharma from a "hold" rating to a "buy" rating in a research note on Tuesday, November 5th. Citigroup lowered their target price on Royalty Pharma from $60.00 to $40.00 and set a "buy" rating for the company in a report on Friday, October 25th. Finally, The Goldman Sachs Group raised their price target on shares of Royalty Pharma from $50.00 to $51.00 and gave the stock a "buy" rating in a report on Wednesday, August 14th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $41.67.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.